Related Experiment Video
Updated: Jun 24, 2026
11:02
Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1
Published on: May 27, 2016
CYP3A5 and ABCB1 genes and hypertension
Murielle Bochud1, Pascal Bovet, Michel Burnier
1Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) et Université de Lausanne, Rue du Bugnon 17, CH-1005 Lausanne, Switzerland. Murielle.Bochud@chuv.ch
Pharmacogenomics
|March 18, 2009
Summary
Genes like CYP3A5 and ABCB1 may influence blood pressure, with effects potentially altered by salt intake. Further research could reveal new ways to control hypertension.
Area of Science:
- Genetics and Cardiovascular Health
Background:
- Hypertension is a leading global health burden, significantly impacted by modifiable factors.
- Genes involved in drug and hormone metabolism (CYP3A5) and transport (ABCB1) are potential regulators of human blood pressure.
Purpose of the Study:
- To review the association between ABCB1 and CYP3A5 gene polymorphisms and blood pressure regulation.
- To explore the mechanisms underlying these genetic influences on blood pressure.
- To discuss the impact of dietary salt intake on these gene-blood pressure relationships.
Main Methods:
- Literature review of studies investigating CYP3A5 and ABCB1 gene polymorphisms.
- Analysis of existing data on gene-blood pressure associations in humans and animal models.
- Examination of research on the interaction between salt intake and these genetic factors.
Main Results:
- Evidence suggests a link between CYP3A5 and ABCB1 gene variations and blood pressure levels.
- The influence of these genes on blood pressure may be modulated by dietary salt consumption.
- These findings highlight a potential genetic component in blood pressure control.
Conclusions:
- The ABCB1 and CYP3A5 genes are implicated in blood pressure regulation.
- Dietary salt intake appears to modify the effect of these genes on blood pressure.
- Confirmation in diverse populations could establish a novel pathway for hypertension management.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:31ABC Transporters: Exporter
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...